Daunomycin, cytosin-arabinoside and VP-16 (DAV) for myeloid blast crisis of CML.

Abstract

Nine patients with myeloid blast crisis of Philadelphia chromosome-positive chronic myelocytic leukemia received 1-3 courses of intensive induction chemotherapy with DAT (daunomycin, cytosin-arabinoside and 6-thioguanin) or DAV (daunomycin, cytosin-arabinoside and VP-16). Eight patients responded with clearing of blasts from peripheral blood giving a response rate of 89%. However, bone marrow aplasia with less than 5% blasts was seen in only 2 patients. These 2 patients subsequently received an allogeneic bone marrow transplant and achieved complete remissions of 3 and 6 month duration. All patients died due to progression of blast crisis. Median survival of the group was 164 days. These results were compared to a historical control group of 31 patients with myeloid blast crisis treated with vincristine and prednisone. Despite a significantly better response rate with DAV or DAT (8 of 9 versus 9 of 31, p = 0.01) survival was not significantly different than that of the control group.

• Authors: B Anger, H Heimpel
• Journal: Blut (Blut) Vol. 58 Issue 6 Pg. 299-301 (Jun 1989) ISSN: 0006-5242 [Print] Germany
• PMID: 2660927 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Cytarabine
• Etoposide
• Thioguanine
• Daunorubicin

Topics

• Adult
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Bone Marrow (pathology)
• Bone Marrow Transplantation
• Cytarabine (administration & dosage, therapeutic use)
• Daunorubicin (administration & dosage, therapeutic use)
• Etoposide (administration & dosage)
• Female
• Humans
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy, genetics, pathology)
• Male
• Philadelphia Chromosome
• Thioguanine (therapeutic use)